公开(公告)号：US20120322088A1

公开(公告)日：2012-12-20

申请号：US13594455

申请日：2012-08-24

Applicant: Dayan Goodenowe

Inventor： Dayan Goodenowe

IPC: G01N27/62 ,  G01N21/78 ,  G01N33/53

CPC classification number: G01N33/6848 ,  G01N33/6893 ,  G01N33/92 ,  G01N2405/00 ,  G01N2405/04 ,  G01N2800/30 ,  G01N2800/38 ,  Y10T436/24

Abstract: Methods for the diagnosis, risk assessment, and monitoring of Autism Spectrum Disorder (ASD) are disclosed. More specifically the present invention relates to the measurement of small molecules (metabolites) in human plasma that are found to have different abundances between persons with a clinical manifestation of ASD and subjects not expressing symptoms of ASD. Further, this invention relates to the monitoring of putative therapeutic strategies designed to ameliorate the biochemical abnormalities associated with ASD.

Abstract translation: 披露了自闭症谱系障碍（ASD）的诊断，风险评估和监测方法。 更具体地说，本发明涉及人类血浆中的小分子（代谢物）的测量，其发现具有ASD的临床表现的人与未表达ASD的症状的受试者之间具有不同的丰度。 此外，本发明涉及监测旨在改善与ASD相关的生化异常的推定治疗策略。

公开(公告)号：US20120035250A1

公开(公告)日：2012-02-09

申请号：US13141035

申请日：2009-12-18

Applicant: M. Amin Khan ,  Paul L. Wood ,  Dayan Goodenowe ,  Rishikesh Mankidy ,  Pearson Ahiahonu

Inventor： M. Amin Khan ,  Paul L. Wood ,  Dayan Goodenowe ,  Rishikesh Mankidy ,  Pearson Ahiahonu

IPC: A61K31/232 ,  C07C69/587 ,  C07C227/18 ,  C07D339/04 ,  C07C231/12 ,  C07C233/47 ,  A61P25/28 ,  A61P25/16 ,  A61P27/02 ,  C07C229/30 ,  A61K31/385

CPC classification number: C07C323/59 ,  C07C229/22 ,  C07C279/14 ,  C07D339/04 ,  C07F9/106

Abstract: Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).

Abstract translation: 本文描述了式I的1-烷基，2-酰基甘油衍生物的合成途径和治疗用途：当向哺乳动物生物系统施用时，其导致独特于醚脂质合成能力的特异性sn-2取代的乙醇胺plasmalogen的细胞浓度增加 的系统。 以这种方式提高特定sn-2取代物种的水平可能导致膜胆固醇水平的降低和淀粉样蛋白分泌的降低。 这些化合物可用于治疗或预防与增加的膜胆固醇，增加的淀粉样蛋白相关的老化疾病和降低的血浆素水平，例如神经变性（包括阿尔茨海默病，帕金森病和年龄相关性黄斑变性），认知障碍，痴呆 ，癌症（例如前列腺癌，肺癌，乳腺癌，卵巢癌和肾癌），骨质疏松症，双相性精神障碍和血管疾病（如动脉粥样硬化，高胆固醇血症）。

公开(公告)号：US20100003761A1

公开(公告)日：2010-01-07

申请号：US12280920

申请日：2007-02-28

Applicant: Lisa Cook ,  Dayan Goodenowe

Inventor： Lisa Cook ,  Dayan Goodenowe

IPC: G01N33/92 ,  C07F9/02

CPC classification number: G06F19/34 ,  C07F9/10 ,  C07F9/106 ,  G01N30/7233 ,  G01N33/6896 ,  G01N2800/2814 ,  G01N2800/2821 ,  G01N2800/50 ,  G01N2800/52 ,  Y10T436/163333

Abstract: The present invention is directed to a method for differentially diagnosing dementia or the risk of dementia in a patient. The method comprises obtaining a sample from the patient; analyzing the sample to obtain quantifying data for one or more than one metabolite marker; comparing the quantifying data for the one or more than one metabolite marker to corresponding data obtained from one or more than one reference sample; and using the comparison to differentially diagnose dementia or the risk of dementia. The method may also assis in assessing dementia or the risk of dementia in a patient. The present invention is also directed to metabolite markers and compounds useful in the present method.

Abstract translation: 本发明涉及用于差异诊断患者痴呆或痴呆风险的方法。 该方法包括从患者获得样品; 分析样品以获得一种或多于一种代谢标记物的量化数据; 将一种或多于一种代谢标记物的量化数据与从一种或多于一种参考样品获得的相应数据进行比较; 并使用比较来差异诊断痴呆或痴呆的风险。 该方法还可以帮助评估患者的痴呆或痴呆风险。 本发明还涉及可用于本发明方法的代谢物标记物和化合物。

公开(公告)号：US20090057553A1

公开(公告)日：2009-03-05

申请号：US12066168

申请日：2006-09-15

Applicant: Dayan Goodenowe

Inventor： Dayan Goodenowe

IPC: B01D59/44

CPC classification number: H01J49/38 ,  H01J49/0031 ,  H01J49/421

Abstract: A novel method and apparatus for Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (FTICR-MS). The FTICR-MS apparatus has a pre-ICR mass separation and filtering device capable of receiving ionized molecules with a plurality of mass to charge (M/Z) sub-ranges. The pre-ICR mass separation and filtering device divides the ionized molecules into a plurality of smaller packets, each of the smaller packets is within one of the M/Z sub-ranges. A magnet in the FTICR-MS apparatus provides a controlled magnetic field. A plurality of ion cyclotron resonance (ICR) cells are arranged in series in the controlled magnetic field and operate independently. An ion trapping device connects the pre-ICR mass separation and filtering device, and stores one of the plurality of smaller packets, prior to sending it to one of the plurality of ICR cells.

Abstract translation: 傅立叶变换离子回旋共振质谱（FTICR-MS）的新颖方法和装置。 FTICR-MS装置具有能够接收具有多个质量（M / Z）子范围的离子化分子的前ICR质量分离和过滤装置。 前ICR质量分离和过滤装置将电离分子分成多个较小的分组，每个较小的分组在M / Z子范围之一内。 FTICR-MS装置中的磁体提供受控的磁场。 多个离子回旋共振（ICR）单元在受控磁场中串联布置并独立运行。 离子捕获装置将ICR前质量分离和过滤装置连接，并且在将其发送到多个ICR单元之一之前存储多个较小分组之一。